1 – 10 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
- 2023
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
Noninvasive detection of any-stage cancer using free glycosaminoglycans
(
- Contribution to journal › Article
- 2021
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
- 2017
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article